Exploring Precision Oncology

Audience

The audience of the Symposium spans a wide range of high-profile stakeholders in clinical and non-clinical cancer research, technology development and patient management.  WIN Symposia attracts an international audience with 50% coming from Europe, 25% from Americas, 15% Middle East & Africa and 10% Asia & Oceania. 

Attendees who are for the vast majority (80%) physicians (or physicians in training), need to understand the role of the current biomarkers, their optimal application, and the emerging new omic tests that will inform future biomarker adoption.

Expected Outcomes Impact

Treating patients without understanding the established and emerging molecular markers for cancer can affect virtually every patient with cancer and every aspect of cancer care, since there are multiple FDA and EMA approved omic biomarkers to refine prognosis, select therapy and/or clinical trials and monitor for cancer recurrence.

There are now biomarkers for selection of hormonal therapies, targeted therapies and immunotherapy. We would like attendees to understand the role of these biomarkers, their optimal application, and the emerging new omic tests that will inform future biomarker adoption.

We will discuss in particular the inclusion of transcriptomics in the biomarker armamentarium, that will require novel algorithms and improved quality of biopsies.

The symposium will also present its first international Molecular Tumor Board to exemplify with patients' concrete cases, submitted by meeting attendees, how to use biomarkers to inform therapeutic choice.

Learning Objectives

The overall learning objectives are: 

1. List available biomarkers for choosing cancer therapy
2. Understand the limitations of current genomic-based biomarkers
3. Understand the objectives and design of research studies and clinical trials assessing new biomarkers for immunotherapy and targeted therapy
4. Understanding differences between prognostic and predictive biomarkers.

CME

WIN 2022 Symposium has been awarded 13 hours of European external CME credits by the European Accreditation Council for Continuing Medical Education (EACCME®).

EACCME Credits 

The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.eu 

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/education/cme/claim-cme-credit-ama 

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. 

Accreditations - Endorsing Organizations

• We are proud to announce that the WIN 2022 Symposium has been endorsed by the American Society of Clinical Oncology (ASCO®) The WIN symposia series has been endorsed by ASCO® for the past 11 consecutive years.
• The European School of Oncology (ESO) has endorsed WIN 2022 Symposium as a Recommended Event